Aequs ₹650 crore warrant issue: key terms for 2026

Overview: What Aequs’ board approved

Aequs Limited has informed stock exchanges about a press release dated September 25, 2026, detailing a board decision to raise capital through a preferential issue of warrants. The board of directors met on Friday, September 25, 2026, and approved issuing warrants that can be converted into equity shares of the company. The proposed fundraise is positioned as an equity infusion by the promoter group through warrants, with 50% payable upfront. The company described this upfront payment as twice the regulatory minimum. The proposal is not yet final and remains subject to shareholder approval and other statutory and regulatory clearances. Aequs is a Belagavi-based, engineering-led, vertically integrated precision manufacturer, and it has said the funds are intended to support expansion plans.

Structure of the fundraise: Preferential warrants

The approved instrument is a preferential issue of warrants convertible into equity shares. Aequs has approved issuance of up to 2,80,71,690 warrants, each convertible into one fully paid-up equity share of face value ₹10. This makes the conversion ratio 1:1, one warrant into one equity share upon payment and exercise. The aggregate issue size is approximately ₹650 crore. In one disclosure, the total fund raise was also quantified as ₹650.00 crore payable in cash. The board approval is an enabling step, with the company set to take the proposal to shareholders.

Who will subscribe: Promoter-group Mellwood Trustee

The subscriber identified for the preferential issue is Mellwood Trustee Services Private Limited. The company described Mellwood Trustee as the trustee of the Melligeri Private Family Foundation and as part of the promoter group. The fundraise is therefore structured as promoter-group participation via warrants, rather than an open-market issuance. Aequs’ filings indicate this is an equity infusion by promoters, routed through the trustee entity. Such transactions typically require strict adherence to pricing and disclosure rules under SEBI regulations, and Aequs has cited the relevant regulatory framework for the floor price.

Pricing details: ₹231.55 per warrant under SEBI ICDR

Aequs said the issue price is ₹231.55 per warrant. The company also disclosed that this price includes a premium of ₹221.55 over the ₹10 face value of the equity share. The price is stated to be the floor price determined under Regulation 164 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Aequs added that the floor price is based on the higher of the 90-trading-day and 10-trading-day volume weighted average prices preceding the relevant date of September 22, 2026. These references matter because preferential issues must comply with SEBI’s pricing safeguards.

Payment schedule: 50% upfront, balance on exercise

A key feature of the proposal is the payment split. Of the total issue size of approximately ₹650 crore, ₹325 crore will be payable upfront upon allotment of the warrants. The company stated that this represents 50% of the issue size and is twice the regulatory minimum. The remaining balance will be payable upon exercise of the warrants and conversion into equity shares. This means the capital inflow is staged: an initial infusion at allotment and the rest only if and when the promoter entity exercises conversion. The structure is important for investors assessing the timing of cash inflows and eventual share issuance.

Timelines: Exercise window and outside date of Dec 31, 2027

Aequs said that, in accordance with applicable regulations, warrants may be exercised within 18 months from the date of allotment. Separately, the company stated that conversion of warrants into equity shares, by making payment of the balance consideration, shall take place on or before December 31, 2027. The disclosures therefore provide both a regulatory exercise framework and a stated outside date for conversion and payment. The actual allotment date is not specified in the provided information, so the 18-month window would begin from that future allotment date, subject to approvals.

Why Aequs is raising funds: Expansion and corporate needs

Aequs said the proceeds are intended to support expansion across its aerospace and consumer businesses. The company also mentioned development of a new facility in Hosur as part of its expansion plans. In addition, Aequs indicated the funds will be used for investments in subsidiaries and joint ventures supporting the expansion, and for general corporate purposes. A PTI report in the provided text also stated that the equity infusion would support the company’s borrowing programme. These uses of funds highlight that the proposed capital raise is linked to capacity and growth investments rather than a single-purpose deployment.

Approvals required: Shareholder vote and regulatory clearances

The board has approved the proposal, but Aequs has clearly stated it requires shareholder approval and other statutory and regulatory approvals as applicable. The company will seek shareholder approval via an Extraordinary General Meeting (EGM) on October 22, 2026. The EGM is scheduled to be held through video conferencing. Until these approvals are obtained and allotment occurs, the fundraising remains a proposed transaction.

Key facts at a glance

Market impact: What investors can measure from the disclosures

From the information provided, the most measurable impact is the potential increase in equity shares if the warrants are fully converted. The company has approved up to 2,80,71,690 warrants, each convertible into one equity share, which defines the maximum potential new share issuance under the proposal. The staged payment structure also provides a clear cash inflow schedule: ₹325 crore at allotment and the remainder only upon exercise. Aequs has also explicitly tied the fundraising to capacity expansion across aerospace and consumer businesses and to the Hosur facility development, which helps investors link the funding to stated growth projects. Pricing has been anchored to the SEBI ICDR floor price methodology, which provides a regulatory basis for the issue price. The transaction is still conditional on shareholder and regulatory approvals, so timelines will depend on completion of those steps.

Analysis: Why the warrant structure and terms matter

The decision to use preferential warrants rather than immediate equity issuance affects both timing and certainty of capital. Aequs will receive ₹325 crore upfront upon allotment, but full receipt of the ~₹650 crore depends on conversion and payment of the balance. The company’s disclosure that the upfront amount is 50% and twice the regulatory minimum is significant because it increases the immediate cash commitment from the promoter subscriber compared with the minimum typically required for warrants. The issue price being the floor price under SEBI ICDR Regulation 164, computed using 90-day and 10-day VWAPs preceding September 22, 2026, signals compliance-focused pricing disclosure. Finally, the stated outside date of December 31, 2027 provides a defined endpoint for when conversion and the remaining payment are expected to occur, subject to allotment and exercise.

Conclusion

Aequs’ board has cleared a preferential issue of up to 2.81 crore warrants to promoter-group entity Mellwood Trustee Services at ₹231.55 each, targeting an equity infusion of about ₹650 crore with ₹325 crore payable upfront. The company has linked the proceeds to aerospace and consumer capacity expansion, including a Hosur facility, along with investments in subsidiaries and joint ventures and general corporate purposes. The proposal now moves to shareholders, with an EGM scheduled for October 22, 2026, and will also require any other applicable regulatory and statutory approvals before allotment and eventual conversion by the stated date of December 31, 2027.